| Similar Articles |
|---|
 |
Managed Care
October 2005
Thomas Morrow |
Incretin Hormones Poised For Better Control of Diabetes Enhanced management continues due to a greater understanding of the intricate glucose balance and the shortfalls of existing medications.   |
Nurse Practitioner
May 2011
Stacey A. Seggelke |
Hitting the target for inpatient glycemic management An understanding of glycemic treatment options for hospitalized patients is essential for good patient outcomes. |
Nursing
November 2009
Christine Kessler |
Glycemic control in the hospital: How tight should it be? Based on recent studies, the answer to that question remains controversial. This article will explore this issue and present current best practices for caring for a patient in the hospital who has diabetes or hyperglycemia. |
American Family Physician
September 15, 2006
Havas & Donner |
Tight Control of Type 1 Diabetes: Recommendations for Patients Physicians play an important role in helping type 1 diabetes patients make essential lifestyle changes to help reduce the risk of microvascular and macrovascular complications. |
American Family Physician
August 1, 2004
Mayfield & White |
Insulin Therapy for Type 2 Diabetes: Rescue, Augmentation, and Replacement of Beta-Cell Function New insulin preparations and a better understanding of insulin physiology provide more options for family physicians attempting to effectively tailor insulin therapy to the needs of individual patients. |
American Family Physician
January 1, 2003
Jennifer B. Marks |
Perioperative Management of Diabetes Diabetic patients who require surgery present special challenges in perioperative management. Special attention must be paid to prevention and treatment of metabolic derangements. |
Nursing Management
January 2012
Lawrence et al. |
Type 2 Diabetes: Growing to Epic Proportions Affecting all age groups and all aspects of a person's life, diabetes is a major public health issue worldwide, requiring lifelong behavioral and lifestyle changes and support. |
Managed Care
May 2006
Fadia T. Shaya & Deshpande |
New Treatment Approaches To Diabetes The goal of diabetes management is maintaining glycemic control while targeting quality of life improvements. |
AskMen.com
April 29, 2001
Joshua Levine |
Do You Have Diabetes? Diabetes is not contagious; people cannot "catch" it from one another. However, certain factors can increase one's risk of developing the disease... |
American Family Physician
May 1, 2001
Beatriz Luna & Mark N. Feinglos |
Oral Agents in the Management of Type 2 Diabetes Mellitus Currently, there are five distinct classes of hypoglycemic agents available, each class displaying unique pharmacologic properties... |
American Family Physician
July 15, 2006
Jennifer D. Goldman-Levine |
Insulin Detemir (Levemir) for Diabetes Mellitus Insulin detemir is suitable as basal insulin in a basal-bolus regimen. In limited research, it has been shown to cause slightly fewer episodes of minor hypoglycemia and no weight gain in patients with type 1 and 2 diabetes, which is a benefit that must be balanced against its higher price. |
The Motley Fool
June 28, 2010
Luke Timmerman |
Orexigen Drug Shows Potential as "Two-Fer" Against Obesity and Diabetes Orexigen's latest drug aims at treating both diabetes and obesity. |
Chemistry World
August 23, 2013
Jessica Cocker |
Plant protein regulates diabetes treatment A plant protein has been used to make a new class of glucose-responsive polymer nanogels that could one day negate the need for diabetes patients to constantly monitor their blood glucose levels and inject themselves with insulin. |
The Motley Fool
March 17, 2005
Stephen D. Simpson |
Patience Rewarded at Last Amylin's battle to get Symlin approved was long and difficult, but success will have its rewards. Should investors take a shot? |
The Motley Fool
June 24, 2008
Brian Orelli |
A Diabetes Drug Delivery Deal Several pharmaceutical companies compete to deliver a diabetes medication that can be taken orally or once-weekly. |
BusinessWeek
December 22, 2003
Arlene Weintraub |
Big Pharma Looks Beyond Insulin Researchers may be on the verge of major new treatments for diabetes and obesity. |
Chemistry World
April 8, 2014
Sarah Kenwright |
Olive oil may offer diabetes protection Spanish scientists say increasing the amount of olive oil in your diet could reduce your risk of developing metabolic syndrome and type 2 diabetes. |
American Family Physician
November 1, 2000 |
Diabetes: Flexible Insulin Regimens for People with Type 1 Diabetes What is insulin?... How do I use insulin?... What is a flexible insulin regimen?... When should I take insulin?... |
Managed Care
November 2005
Thomas Morrow |
This Nutritional Supplement Might be an Inexpensive Way to Improve Glycemic Control for the 18 Million Americans with Diabetes The review of the existing literature suggests that chromium picolinate with biotin offers people with diabetes hope for the future at a price that is less than what would be their copayment for a normal monthly generic drug. |
American Family Physician
May 1, 2001 |
Treatment Options for Type 2 Diabetes -- What's Available? What are the different steps in managing my diabetes? What are the different types of medicines used to treat type 2 diabetes and how do they work? |
American Family Physician
June 15, 2006
Ezzo & Ambizas |
Exenatide Injection (Byetta): Adjunctive Therapy for Glycemic Control Exenatide is an expensive, inconvenient drug that has no proven benefits over other drugs for diabetes management, including insulin. |
The Motley Fool
October 2, 2007
Brian Orelli |
Amylin's Bittersweet FDA News Diabetes drug moves ahead, but not as much as the company wanted. If the FDA rejection was due to safety issues, that wouldn't bode well for Amylin's plans to develop the active ingredient in SYMLIN as a weight-loss drug. Investors, take note. |
Nurse Practitioner
October 2010
Hill & Appel |
Diagnosing Diabetes with A1C: Implications and Considerations for Measurement and Surrogate Markers Now that the ADA has officially positioned the assay as a means of diagnosis and monitoring, it is another tool NPs must access properly when helping patients manage diabetes and treatment. |
American Family Physician
November 1, 2003
Turok et al. |
Management of Gestational Diabetes Mellitus Although the disorder affects approximately 2.5 percent of pregnant women and has been the subject of extensive research, its diagnosis and management continue to be debated. |
IEEE Spectrum
January 2011
Sandra Upson |
Bionic Pancreas Artificial organ could improve control over diabetes |
Food Processing
August 2013
Mark Anthony |
The Condemnation of Carbohydrates: A Food Manufacturers Guide to Understanding Diabetes The commonly held notion that sugar intake equals diabetes is a kind of unofficial dogma. But like many dogmas, this one falls apart upon closer examination. |
The Motley Fool
November 30, 2007
Brian Orelli |
Analyzing Amylin Amylin Pharmaceuticals holds its R&D day to update investors on the marketing strategy of its two diabetes products, as well as the development of its pipeline. |
The Motley Fool
July 8, 2011
Luke Timmerman |
Amylin, Alkermes Once-Weekly Diabetes Drug Passes Heart Trial What does this mean for the drug companies? |
The Motley Fool
September 30, 2011
Brian Orelli |
A Drug Market That's 366 Million Strong Diabetes drugs have potential. |
HHMI Bulletin
Fall 2012
Sarah C. P. Williams |
The Fat You Can't See Without the liver acting as a filter and energy producer, a person can't survive, and no artificial organ can perform all of its duties. But in one in three Americans -- and similar numbers in other developed nations -- the liver has lost its luster. |
American Family Physician
April 15, 2004
Rao, Disraeli & Mcgregor |
Impaired Glucose Tolerance and Impaired Fasting Glucose Impaired glucose tolerance and impaired fasting glucose form an intermediate stage in the natural history of diabetes mellitus. |
Food Processing
December 2007
Mark Anthony |
Nutrition Beyond the Trends: Cinnamon and Blood Sugar Science connects cinnamon to the stabilization of blood sugar for many individuals. |
AskMen.com
Alex Santoso |
What You Should Know About Diabetes Not many men understand what diabetes is, why it's very bad for them (it is one of the leading causes of impotence), what they can do to avoid getting it or how to treat it. |
Science News
April 14, 2007
Janet Raloff |
Cinnamon and Diabetes--Disease Type Appears to Matter Many teens with type 1 diabetes need help maintaining tight control of their blood sugar. Cinnamon isn't the answer, a new study finds, even though the spice appears to help moderate blood sugar in persons with type 2 diabetes. |
The Motley Fool
June 29, 2009
Brian Orelli |
Lantus Results: Reply Hazy, Try Again Later Drugmaker Sanofi's problems become murkier. Investors are relieved that the data is out -- Sanofi is up about 4.5% at the moment -- but it seems prudent to be cautious here. |
American Family Physician
October 15, 2003
Gavin et al. |
Reducing Cardiovascular Disease Risk in Patients with Type 2 Diabetes By increasing patient awareness of the link between diabetes and heart disease, family physicians can encourage patients to take medications (including aspirin), stop smoking, lower blood pressure, and lower cholesterol and blood glucose levels. |
Nursing
September 2010
Margaret M. Bolton |
Sounding the alarm about metabolic syndrome Any health problem that affects a third of American adults is sure to impact your nursing practice. Metabolic syndrome, a growing and commonly silent condition, poses a significant public health crisis. |
Chemistry World
July 3, 2012
Andrew Turley |
BMS and AstraZeneca buy Amylin for $7bn Pharma giants Bristol-Myers Squibb and AstraZeneca have teamed up to buy US biotech Amylin for $7 billion, further strengthening their position in the burgeoning market for diabetes drugs. |
Managed Care
May 2007
Rachel M. Renshaw |
Keys to Diabetes Control? Patience, Persistence, and Perseverance Careful attention to a comprehensive treatment plan could forestall or prevent the need to add drugs and costs to a patient's regimen. |
The Motley Fool
June 27, 2005
Stephen D. Simpson |
Sniffing Out a Possible Diabetes Blockbuster Inhaled insulin has been a Holy Grail of diabetes care. Will it live up to lofty expectations? Pfizer, Sanofi-Aventis, and Lilly are all interesting in their own right as high-quality pharmaceutical companies, and more aggressive investors should take a look at Nektar and Alkermes, as well. |
The Motley Fool
October 21, 2011
Brian Orelli |
Full of News, but Worth a 15% Gain? Amylin serves up an appetizer. |
The Motley Fool
October 2, 2009
Brian Orelli |
Warning! Potential Blockbuster Ahead It's a little early to call it, but it looks like Bristol-Myers Squibb and AstraZeneca have a potential blockbuster on their hands with their new diabetes drug. |
Pharmaceutical Executive
May 1, 2009 |
The Fate of Mannkind Al Mann has sunk almost $1 billion of his own money into a new insulin delivery system. Will FDA be persuaded? |
American Family Physician
March 15, 2001
Goutham Rao |
Insulin Resistance Syndrome Insulin resistance can be linked to diabetes, hypertension, dyslipidemia, cardiovascular disease and other abnormalities. Because resistance usually develops long before these diseases appear, identifying and treating insulin-resistant patients has potentially great preventive value... |
The Motley Fool
September 22, 2010
Brian Orelli |
Better Buy: Amylin Pharmaceuticals or MannKind? It's a diabetes-drug showdown. |
The Motley Fool
August 23, 2005
Stephen D. Simpson |
A Cure for Amylin's Stock? Shares moved up after promising results from a diabetes-drug test. But will the gains last? |
The Motley Fool
June 16, 2010
Brian Orelli |
A Drop on Bad News, but It Was a Long Shot Anyway Bydureon, Amylin Pharmaceuticals and Eli Lilly's once-weekly version of their twice-daily Byetta, has been beating up other diabetes drugs in a series of head-to-head clinical trials but it will have a tough time going after the monotherapy market. |
Managed Care
July 2004
Udaya M. Kabadi |
Cost-Effective Management of Hyperglycemia in Patients with Type 2 Diabetes Using Oral Agents Sulfonylureas are cost-effective and also may be the only oral agents that inhibit processes inducing hyperglycemia by improving insulin secretion and insulin resistance. New long-acting agents hold even greater promise. |
The Motley Fool
August 21, 2007
Brian Orelli |
Sweet Phase 3 Data Although diabetes drugs have come under fire lately, insulin maker Novo Nordisk is moving full steam ahead with its newest drug to help fight type 2 diabetes. |
The Motley Fool
July 22, 2009
Brian Orelli |
The Blockbuster Around the Corner Amylin Pharmaceuticals' Byetta sales are improving, but is it enough? |
